- IQ-AI expects sales momentum to continue after first-half revenue doubles
- IQ-AI trebles in value after impressive run of updates
- IQ-AI present their plans to finance brain tumour trial to evaluate efficacy of Gallium Maltolate
Quick facts: IQ-AI Ltd
IQAI was created to accelerate the translation and commercialisation of proven imaging technologies, from the laboratory to routine clinical use, that have potential to dramatically impact the quality of life for patients facing brain tumours and other chronic diseases.
Brain tumour patients and especially those diagnosed with glioblastoma multiforme (GBM) for example face a dismal prognosis. Despite tremendous global efforts that span decades, only incremental improvements have been made in survivability and progression free survival.
The unmet clinical need of GBM and other diseases motivates IQAI to continuously innovate and deliver validated products that benefit patients. Since its inception, the company has aggressively proliferated its product portfolio, accelerated product and technology development, and obtained market clearance for new global territories.
27 Aug 2021
(, ) () reported a doubling of revenue in the first half and said it expects this level of sales to continue for the rest of the year.
Revenue rose by 104% to GBP238,438 in the six months to end-June from GBP116,842 last year, while losses shrank by 44% to GBP207,135.
“We are increasingly optimistic about the potential new sales that can be realized with our channel partners and distributors and expect first-half sales momentum to continue for the remainder of the current financial year,” the company said.
“During the period, we regained momentum on sales prospects that were slowed by the Covid-19 pandemic, reached new milestones in our technology and product roadmap, and made the strategic decision to sponsor a Phase I Clinical Trial using an oral drug candidate to combat glioblastoma multiforme (GBM) in patients,” it added.
11 Jun 2021
IQ-AI Limited () said its synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office.
The technology eliminates the need to intravenously inject contrast agent during medical imaging procedures, the company said, adding that the patent underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.
04 Jun 2021
IQ-AI Limited () subsidiary Imaging Biometrics said its brain tumour imaging platform has been purchased by the Los Angeles County Hospital.
The deal follows the recent installation of the IB Clinic technology at the Keck Medical Center of USC, also in LA. The two run a healthcare network serving around 10mln patients.
09 Nov 2020
() is firing on all cylinders after a few busy weeks that saw its share price rocket three-fold.
The AIM-listed investor, which focuses on the tech sector, touched a five-year high last week after a triple dose of good news.
15 Apr 2021
Michael Schmainda, co-founder and CEO of ‘s () subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.
This type of cancer, Glioblastoma is the most common and aggressive primary brain cancer and has limited treatment options and a dismal prognosis.
If the trial is successful IQAI intends to apply to the US Food and Drug Administration (FDA) for orphan drug status under the FDA’s orphan drug designation programme, which grants market exclusivity in the US for seven years following approval of the drug.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…
1 hour, 55 minutes ago
Michael Schmainda, co-founder and CEO of IQ-AI Limited’s (LON:IQAI) subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.
This type of cancer, Glioblastoma is the most common…
1 week, 3 days ago
1 week, 4 days ago
2 weeks, 1 day ago
3 hours, 36 minutes ago